Patent SG-11201803834U-A (SG)
Title: Methods for treating conditions associated with masp-2 dependent complement activation
Inventor: DEMOPULOS GREGORY
IPC: C07K16/40
Filed: 2016-11-09
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111010111111111111111111011111111011111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ....r „...1 WO 2017/083371 Al 18 May 2017 (18.05.2017) WIPO I PCT (51) International Patent Classification: A61K 39/00 (2006.01) A61P A61K 39/395 (2006.01) C07K A61P 7/02 (2006.01) (21) International Application Number: (22) International Filing Date: 9 November (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/252,814 9 November 2015 (09.11.2015) 62/406,726 11 October 2016 (11.10.2016) (71) Applicants: OMEROS CORPORATION Elliott Avernue West Seattle, WA 98119 (US). UNIVER- SITY OF LEICESTER [GB/GB]; Leicestershire LE1 7RH (GB). _ (72) Inventors; and (74) Agent: QUINTON, Tineka, J.; Omeros Corporation, 201 37/02 (2006.01) Elliott Avenue West, Seattle, WA 98119 (US). 16/40 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/US2016/061113 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 2016 (09.11.2016) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, US ZW. US (84) Designated States (unless otherwise indicated, for every [US/US]; 201 kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, University Road, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Gregory, A. [US/US]; SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, WA 98040 (US). GW, KM, ML, MR, NE, SN, TD, TG). NE 36th Street Bel- Hans-Wilhelm Declarations under Rule 4.17: Leicestershire LE18 — as to the identity of the inventor (Rule 4.17(0) [Continued on next page] — (71) Applicants : DEMOPULOS, 4845 Forest Avenue SE, Seattle, DUDLER, Thomas [CH/US]; 13410 = levue, WA 98005 SCHWAEBLE, (US). 36 The Green, Mountsorrel, [DE/GB]; 3GF (GB). = = = = LDH = 100 *** CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIV- Change from Baseline over Time *p-x0.05 .* p<0 01 p4) 001 (54) Title: METHODS FOR TREATING ATION = = = = 200- W . = _ 5 provides associated an amount *. * Lestimnalple Biwa@ Waak 7 6 8 9 10 11 12 ViIcelcs 4 4 3 2 2 3 FIG. 59 methods of inhibiting the effects of MASP-2-dependent complement activation with hematopoietic stem cell transplant. The methods comprise the step of ad- of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent comple- = -144 _ -200 __ -300 Il -500 11 Ir...' M en No. ofPaticats GC 0 IN 1-1 N (57) : In one aspect, the invention in a human subject suffering from TMA C ministering, to a subject in need thereof, ment activation. WO 2017/083371 Al MIDEDIMOMMIDIROMMIEMERNMOMOVOIMIE — as to applicant's entitlement to a patent (Rule 4.17(0) Published: apply for and be granted — with sequence listing part of description (Rule 5.2(a)) — with international search report (Art. 21(3))